<tbody id="ff6si"><div id="ff6si"></div></tbody>
  • <track id="ff6si"></track>

    1. <option id="ff6si"></option>

    2. <option id="ff6si"></option>
      1. <track id="ff6si"></track>

          Fresenius Group Overview

          July 03, 2019

          Fresenius Medical Care expands clinical research activities

          • “No other provider of clinical development services understands the medical needs of people living with kidney disease as well as we do", said Dr. Frank Maddux, Chief Medical Officer of Fresenius Medical Care.

            Download Image (JPG 1.25 MB)
          Download image

          Fresenius Medical Care, the world’s largest provider of dialysis products and services, is expanding its clinical research activities. Frenova Renal Research (Frenova), previously a Fresenius Medical Care North America subsidiary, will now offer its services worldwide and will be integrated into the new Global Medical Office headed by Dr. Frank Maddux, Chief Medical Officer.

          Frenova offers services for the clinical development of medicines and medical products in the field of kidney research. This offering, previously limited to North America, will now be linked with the corresponding services of Fresenius Medical Care’s Europe, Middle East and Africa (EMEA) and Latin America regions and bundled under Frenova. This will enable the company to draw on a network of more than 550 researchers at over 350 locations.

          “Frenova is active at the intersection of clinical research and patient care,” said Dr. Maddux. “No other provider of clinical development services understands the medical needs of people living with kidney disease as well as we do. By making this expertise available worldwide, we will enable a faster, more efficient development of medications and other products. This is an additional, important building block for improving their quality of life.” 

          Disclaimer
          This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

          青草青青